Strides in STXBP1 Research
What’s new in September of 2026
Researchers in Amsterdam, led by Matthijs Verhage, used single‑cell RNA sequencing to look at how reduced levels of the STXBP1 gene affect individual brain cell types in a mouse model of STXBP1‑RD. Even though all major brain cell types were still present in normal proportions, the function of many cells was disrupted. The biggest changes happened in two groups of neurons: Deep‑layer excitatory (glutamatergic) neurons, which send long‑range signals and help coordinate brain circuits, and Sncg inhibitory (GABAergic) interneurons, small, specialized neurons with unique firing patterns. Both excitatory and inhibitory neurons showed problems in genes involved in synaptic communication, energy use, and protein production. A key finding was that neurons were making fewer new proteins, which is essential for healthy synaptic function and learning. Astrocytes, which normally don’t use STXBP1, also showed major gene‑expression changes, likely because they were reacting to abnormal neuronal. They also found that the gene‑expression changes in these mice did not resemble other epilepsy or neurodevelopmental disorders, suggesting STXBP1‑RD has a distinct biological signature. Finally, the researchers linked certain gene‑expression patterns to seizure‑like behaviors in the mice.
Researchers led by a group from Northwestern University published a paper descriging a new a new tool called EpiPred, a machine‑learning model designed to help doctors and researchers figure out which STXBP1 gene changes are truly disease‑causing. Many STXBP1 missense variants are currently labeled “uncertain,” meaning that we don’t know if they cause disease or not. The EpiPred program was trained specifically on STXBP1 biology and outperformed other types of prediction tools. The researchers tested its predictions in lab experiments that measured how specific mutations affect the STXBP1 protein, i.e. its amount, stability, solubility, and ability to interact with its partner protein, syntaxin‑1. These lab results matched the model’s predictions well and even helped identify variants that may have been misclassified in the past. The team also built a public website where families, clinicians, and scientists can look up any STXBP1 missense variant (https://carvill-lab.shinyapps.io/epipred-shiny/). Overall, the study shows that combining gene‑specific machine learning with real biological testing can improve diagnosis, guide clinical trial enrollment, and support future precision therapies for STXBP1‑related disorders.
High-calorie high-fat diets (HFD) have been associated with brain diseases such as neurodegenerative dementias, like Alzheimer’s disease. Japanese researchers looked at how HFD in mice can directly harm brain function. They found that HFD causes a decrease in the expression (i.e protein levels) of a gene called PQBP1, which normally helps neurons correctly process RNA and build healthy synapses. When PQBP1 protein drops, several important brain proteins are produced in faulty, “mis‑spliced” forms that weaken communication between neurons. Importantly, two of these proteins (CASK and Cacnb1) normally interact with STXBP1. The diet‑induced disruption of this PQBP1–CASK/Cacnb1–STXBP1 pathway leads to fewer and weaker synapses and measurable learning and memory problems in mice. The researchers also show that boosting PQBP1 or restoring normal versions of these proteins, via gene therapy, can reverse many of the brain and cognitive deficits.
A clinician from the University of Arkansas published a review article on epilepsy with myoclonic‑atonic seizures. This type of epilepsy, also called Doose syndrome, is a childhood epilepsy that begins suddenly and causes several types of generalized seizures, especially brief “drop attacks” where a child jerks and then loses muscle tone. The review explains how doctors diagnose the condition, what treatments work best, and how genetics is reshaping care. Most children respond to medicines like valproate, clobazam, or ethosuximide, and the ketogenic diet is especially effective when seizures are hard to control. The article also highlights that some children have an underlying genetic cause, including STXBP1, and that future therapies may increasingly target these specific biological pathways. Although many children eventually outgrow the seizures, some continue to face learning or behavioral challenges, making early diagnosis and tailored treatment important.